A 12 month, randomized, open-label, multicenter, study to assess the long term safety of aliskiren 150mg alone and 300mg alone or with the optional addition of hydrochlorothiazide (12.5mg or 25mg) in patients with essential hypertension.

Trial Profile

A 12 month, randomized, open-label, multicenter, study to assess the long term safety of aliskiren 150mg alone and 300mg alone or with the optional addition of hydrochlorothiazide (12.5mg or 25mg) in patients with essential hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2011

At a glance

  • Drugs Aliskiren; Hydrochlorothiazide
  • Indications Essential hypertension
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Dec 2011 Results published in Clinical Drug Investigation.
    • 07 Nov 2011 Actual initiation date (June 2004) added as reported by ClinicalTrials.gov.
    • 07 Nov 2011 Actual end date (October 2005) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top